JLJörn Lausen

Jörn Lausen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jörn Lausen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Olga N. Kuvardina

    Georg-Speyer Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany

    4 shared publications
  • Stephan Kolodziej

    Georg-Speyer Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany

    3 shared publications
  • Achim Leutz

    Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125 Berlin, Germany

    2 shared publications
  • Halvard Bonig

    Institute for Transfusion Medicine and Immunohematology, Goethe University and German Red Cross Blood Service BaWueHe, Frankfurt, Germany

    2 shared publications
  • Helge Hussong

    Georg-Speyer Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany

    2 shared publications
  • Hubert Serve

    Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany

    2 shared publications

Latest Publications

  • Open Access

    RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation

    by Olga N. Kuvardina, Julia Herglotz, Stephan Kolodziej, Nicole Kohrs, Stefanie Herkt, Bartosch Wojcik, Thomas Oellerich, Jasmin Corso, Kira Behrens, Ashok Kumar, et al.

    Key Points: RUNX1 inhibits erythroid differentiation by downregulation of the erythroid gene expression program. RUNX1 can act as an activator and repressor during megakaryocytic differentiation and counteracts the activity of TAL1.


  • Open Access

    PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation

    by Stephan Kolodziej, Olga N. Kuvardina, Thomas Oellerich, Julia Herglotz, Ingo Backert, Nicole Kohrs, Estel.La Buscató, Sandra K. Wittmann, Gabriela Salinas-Riester, Halvard Bonig, et al.

    The transcription factor Tal1 is a critical activator or repressor of gene expression in hematopoiesis and leukaemia. The mechanism by which Tal1 differentially influences transcription of distinct genes is not fully understood. Here we show that Tal1 interacts with the peptidylarginine deiminase IV (PADI4). We demonstrate that PADI4 can act as an epigenetic coactivator through influencing H3R2me2a. At the Tal1/PADI4 target gene IL6ST the repressive H3R2me2a mark triggered by PRMT6 is counteracted by PADI4, which augments the active H3K4me3 mark and thus increases IL6ST expression. In contrast, at the CTCF promoter PADI4 acts as a repressor. We propose that the influence of PADI4 on IL6ST transcription plays a role in the control of IL6ST expression during lineage differentiation of hematopoietic stem/progenitor cells. These results open the possibility to pharmacologically influence Tal1 in leukaemia.


  • Open Access

    The T-Cell Oncogene Tal2 Is a Target of PU.1 and Upregulated during Osteoclastogenesis

    by Nadine Courtial, Christian Mücke, Stefanie Herkt, Stephan Kolodziej, Helge Hussong, Jörn Lausen

    Transcription factors play a crucial role in regulating differentiation processes during human life and are important in disease. The basic helix-loop-helix transcription factors Tal1 and Lyl1 play a major role in the regulation of gene expression in the hematopoietic system and are involved in human leukemia. Tal2, which belongs to the same family of transcription factors as Tal1 and Lyl1, is also involved in human leukaemia. However, little is known regarding the expression and regulation of Tal2 in hematopoietic cells. Here we show that Tal2 is expressed in hematopoietic cells of the myeloid lineage. Interestingly, we found that usage of the Tal2 promoter is different in human and mouse cells. Two promoters, hP1 and hP2 drive Tal2 expression in human erythroleukemia K562 cells, however in mouse RAW cells only the mP1 promoter is used. Furthermore, we found that Tal2 expression is upregulated during oesteoclastogenesis. We show that Tal2 is a direct target gene of the myeloid transcription factor PU.1, which is a key transcription factor for osteoclast gene expression. Strikingly, PU.1 binding to the P1 promoter is conserved between mouse and human, but PU.1 binding to P2 was only detected in human K562 cells. Additionally, we provide evidence that Tal2 influences the expression of the osteoclastic differentiation gene TRACP. These findings provide novel insight into the expression control of Tal2 in hematopoietic cells and reveal a function of Tal2 as a regulator of gene expression during osteoclast differentiation.


  • Contributions of the Histone Arginine Methyltransferase PRMT6 to the Epigenetic Function of RUNX1

    by Joern Lausen

    Hematopoietic differentiation is directed by transcription factors such as RUNX1. RUNX1 binds to specific DNA binding sites in regulatory elements of genes and recruits epigenetic cofactors to target loci. In this way histone modification patterns and the chromatin environment are altered, which results in adjusted gene expression. The process of transcription factor binding and cofactor recruitment is dynamic and strongly influenced by specific posttranslational modifications, which are triggered by signaling. In this way cellular signaling is integrated at the epigenetic level by transcription factors. The identification of epigenetic cofactors and the study of their epigenetic influence on transcription is crucial for the understanding of transcription factor function in differentiation and disease. In this article, the recent observation that RUNX1 is associated with the protein arginine methyltransferase 6 will be reviewed. PRMT6 triggers H3R2me2a at RUNX1 target genes; this histone modification negatively influences the positive H3K4me3 mark and this way acts repressive. The RUNX1/PRMT6 association has an impact on bivalent histone marks. Upon differentiation, a RUNX1 corepressor complex with PRMT6 is exchanged with a RUNX1 coactivator complex. Furthermore, the potential cross talk of transcription factors and epigenetic cofactors with histone marks will be discussed.


  • Open Access

    Tal1 regulates osteoclast differentiation through suppression of the master regulator of cell fusion DC‐STAMP

    by Nadine Courtial, Jeske J. Smink, Olga N. Kuvardina, Achim Leutz, Joachim R. Göthert, Jörn Lausen

    The balance between bone‐forming osteoblasts and bone‐resorbing osteoclasts is crucial to bone homeostasis, an equilibrium that is disturbed in many bone diseases. The transcription factor Tal1 is involved in the establishment of hematopoietic stem cells in the embryo and is a master regulator of hematopoietic gene expression in the adult. Here, we show that Tal1 is expressed in osteoclasts and that loss of Tal1 in osteoclast progenitors leads to altered expression of >1200 genes. We found that DC‐STAMP , a key regulator of osteoclast cell fusion, is a direct target gene of Tal1 and show that Tal1 represses DC‐STAMP expression by counteracting the activating function of the transcription factors PU.1 and MITF. The identification of Tal1 as a factor involved in cell fusion contributes to the understanding of osteoclast‐associated diseases, including osteoporosis.—Courtial, N., Smink, J. J., Kuvardina, O. N., Leutz, A., Göthert, J. R., Lausen, J. Tal1 regulates osteoclast differentiation through suppression of the master regulator of cell fusion DC‐STAMP . FASEB J. 26, 523–532 (2012). www.fasebj.org


  • Open Access

    Targets of the Tal1 Transcription Factor in Erythrocytes

    by Jörn Lausen, Ole Pless, Fransisca Leonard, Olga N. Kuvardina, Benjamin Koch, Achim Leutz